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Abstract
Background: Former studies on smoking as a risk factor for Philadelphia‐negative 
myeloproliferative neoplasms (MPNs) have mainly been carried out in women’s co-
horts and studies with various definitions of MPNs. Herein, we conducted a cohort 
study with register‐based follow‐up of a general population from Denmark, to vali-
date and substantiate prior observations.
Methods: In the Danish Health Examination Survey cohort, we used the Cox propor-
tional‐hazards model adjusted for age, sex, body mass index, and level of education, 
to calculate hazard ratios (HRs), to investigate, whether daily smokers or occasional/
ex‐smokers had an increased risk of MPNs compared to never‐smokers.
Results: From the time of data collection (September 2007 to October 2008) until 1 
January 2015, 70 individuals were diagnosed with MPNs among 75 896 study par-
ticipants. Similar results were observed in both the age and sex adjusted analysis and 
the multivariable analysis. The multivariable HR of any MPN diagnosis for daily 
smokers was 2.5 (95% CI: 1.3‐5.0). For essential thrombocytosis, polycythemia vera, 
myelofibrosis, and MPN‐unclassified, the HRs were 1.8 (95% CI: 0.5‐5.8), 1.7 (95% 
CI: 0.5‐5.8), 4.3 (95% CI: 0.9‐19), and 6.2 (95% CI: 1.5‐25), respectively. Among 
occasional/ex‐smokers the corresponding HRs were 1.9 (95% CI: 1.1‐3.3), 1.5 (95% 
CI: 0.6‐3.7), 0.8 (95% CI: 0.3‐2.4), 0.9 (95% CI: 0.2‐4.4), and 6.2 (95% CI: 1.8‐21). 
Participants, who smoked >15 g/day, had an overall HR of 3.4 (95% CI: 1.4‐8.2) for 
any MPN diagnosis, while participants who smoked ≤15 g/day, had an overall HR of 
2.1 (95% CI: 0.9‐4.7).
Conclusion: Smoking was associated with MPN development when comparing 
smokers and never‐smokers. Further studies investigating smoking in MPNs are 
warranted to substantiate our findings.
K E Y W O R D S
epidemiology, essential thrombocythemia, myeloproliferative neoplasms, polycythemia vera, primary 
myelofibrosis, tobacco smoking
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1 |  INTRODUCTION
Smoking is associated with a chronic low‐grade inflamma-
tory state as evidenced by increased levels of several pro‐in-
flammatory cytokines, in vivo activation of leukocytes and 
platelets, endothelial dysfunction, and systemic oxidative 
stress.1 Additionally, smoking is associated with a pattern 
of persistent chronic hypoxic hyperstimulation of myeloid 
cells assessed by elevated levels of the hematocrit, leuko-
cytosis, monocytosis, and occasionally thrombocytosis.1 
Interestingly, these inflammatory components and blood cell 
indices are also a typical presentation of the Philadelphia‐
negative chronic myeloproliferative neoplasms (MPNs), en-
compassing essential thrombocythemia (ET), polycythemia 
vera (PV), myelofibrosis (MF), and unclassifiable MPNs 
(MPN‐U).2
The biological continuum of MPNs—from ET through 
PV to the advanced myelofibrosis state—has been proposed 
to constitute “A Human Inflammation Model for Cancer 
Development.”3 According to this model, chronic inflam-
mation, which is also generated by the neoplastic cells 
themselves, may be an important driver of clonal evolution, 
premature atherosclerosis, and development of second can-
cers.4,5 The perspectives of smoking as a contributing factor 
for MPNs have most recently been thoroughly described by 
Hasselbalch,3 including previous important epidemiological 
studies demonstrating an association of smoking and MPNs.6-
8 Consequently, it has been highlighted that smokers and pa-
tients with MPNs share features of an increased inflammatory 
burden, including, upregulation of important molecular path-
ways and transcriptions factors3,9 These shared factors, all of 
which are vigorously amplified,10-13 are known to be involved 
in tumorigenesis and cancer progression.14 Owing to these 
similarities and the model of chronic inflammation and its role 
in the clonal evolution and progression of MPNs, it is tempt-
ing to suggest smoking as one of several potent inflammatory 
stimuli potentially triggering and driving the MPN‐clone.
This cohort study with register‐based follow‐up of se-
lected individuals from the general population in Denmark, 
aimed to investigate whether smokers had an increased risk 
of MPNs compared to never‐smokers.
2 |  METHODS
We used data from the population‐based study “The Danish 
Health Examination Survey” (DANHES).15 DANHES con-
formed to the principles of the Declaration of Helsinki and 
written informed consent was obtained from all partici-
pants. The National Institute of Public Health, University 
of Southern Denmark, and the Danish Data Protection 
Agency gave their permission to carry out this specific 
study (J.nr 2007‐54‐0017). An approval from the Danish 
Health Authority and the National Committee on Health 
Research Ethics was not needed, as registry‐based studies are 
exempted.
In DANHES, all citizens between 18 and 99 years of age 
from 13 of the 98 municipalities in Denmark (n = 538 497) 
were invited by letter to fill out two internet‐based question-
naires; a basic questionnaire containing questions on so-
ciodemographic, health behavior including smoking status, 
self‐reported health, and living conditions plus a supplemen-
tary questionnaire concerning diet. A total of 76 484 citizens, 
corresponding to 14% of the general population in the respec-
tive municipalities, filled out the questionnaires. Data were 
collected between September 2007 and October 2008.
Smoking status was reported as never, daily, current but not 
daily (reported in categories of at least once per week but not 
daily, once per month, or rarer than once per month), and for-
mer smoking. Participants were categorized as never‐smok-
ers, occasional smokers (ie current non‐daily) combining 
ex‐smokers, and daily smokers. Occasional and ex‐smokers 
were combined due to a relatively low number of cases in the 
two categories. Amount of smoking was reported separately 
for cigarettes, cheroots and cigars (in numbers per day), and 
pipe tobacco (in grams per week). Assuming 1 cigarette to 
be equivalent to 1 g of tobacco, 1 cheroot to 3 g of tobacco, 
1 cigar to 5 g of tobacco, and dividing the reported grams of 
weekly pipe tobacco with 7, a measure of daily amount of 
smoking in g/day was calculated as a sum of the tobacco from 
the individual types. Cumulative smoking was calculated in 
pack‐years based on information on duration of smoking 
and amount of consumed tobacco: one pack‐year was 20 g 
smoked daily for one year. Participants with no available data 
on smoking status were excluded from the analyses. Level 
of education as well as body mass index (BMI) was catego-
rized into three groups (<10, 10‐12, and ≥12 years and <25, 
25‐30, and >30 kg per square meter, respectively).
Participants’ unique civil registration number enabled in-
dividual level linkage of data with national registries.16 The 
civil registration numbers given at birth or immigration to all 
Danish citizens ensured that different longitudinal measures 
for all participants could be obtained, including information 
on all in and out hospital visits and associated diagnosis codes 
from the Danish National Patient Registry,17 including infor-
mation on MPN diagnosis, as well as information on vital sta-
tus and emigration recorded in the Danish Civil Registration 
System.18 We used the following codes from the International 
Classification of Diseases to identify patients with MPNs; 
ET: 8th revision = 287.29, 10th revision = D47.3, D75.2, 
PV: 8th revision = 208.99, 10th revision = D45, MF: 8th 
revision = 209, 10th revision = D47.4, C94.4, C94.5, and 
MPN‐U: 10th revision = D47.1. Participants, who had any 
MPN diagnosis prior to baseline, were excluded. Any re-
cords of either ET, PV, MF, or MPN‐U from baseline until 
end of follow‐up were defined as MPN events in this study. 
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We followed everyone from baseline to either time of MPN 
diagnosis, loss to follow‐up, death, or end of follow‐up at 1 
January 2015. To increase the accuracy of newly recorded 
MPNs, participants who were subsequently diagnosed with 
“cytosis by other causes” (secondary polycythemia; 10th re-
vision: D75.1) were excluded to avoid possible misclassifica-
tion bias; a method previously described.19
2.1 | Statistical analysis
We calculated hazard ratios (HR) and 95% confidence inter-
vals (95% CI) using Cox proportional‐hazards models with 
delayed entry. Age (in days) was used as the underlying time 
axis to ensure maximal adjustment for confounding by age.20 
We examined the Cox proportional‐hazards assumption by 
plots of log(−time) against log(−log(survival probability)) 
and by introducing interaction terms between age and al-
cohol intake in the model, with no violations detected. We 
performed both an age and sex adjusted analysis comparing 
daily smokers and occasional/ex‐smokers with never‐smok-
ers and a multivariable analysis adjusted for age, sex, and 
level of education as well as BMI, as studies have shown that 
obesity is independently associated with inflammation and 
MPNs.21-23 Information on height or weight (and thus BMI) 
was missing for four percent of the participants. To avoid 
reducing the sample size, a dummy variable indicating miss-
ing BMI value was constructed and used in analyses. Former 
studies have not been able to show an association with alco-
hol, why we refrained from adjusting for this.6,7 Daily smok-
ers were further divided in two groups based on daily amount 
of smoking (>15 g/day and ≤15 g/day) and compared with 
never‐smokers, to look at the effect of amount of daily smok-
ing on the risk estimates. Similarly, we examined the risk 
estimate per 10 pack‐years of smoking to investigate the 
effect of cumulative smoking in ever‐smokers. Descriptive 
statistics were presented as medians for continuous vari-
ables and as frequencies and percentages for categorical vari-
ables. Results were considered statistically significant at the 
P < 0.05 level. All analyses were performed using SAS 9.4 
(The SAS Institute, Cary, NC, USA).
3 |  RESULTS
In total, 76 484 survey participants were potentially eligible 
for inclusion. Of those, 588 participants were subsequently 
excluded; 510 participants due to missing information 
on smoking status, 54 participants with a MPN diagno-
sis prior to data collection, 23 participants due to errors 
in the registration key, and one participant due to a diag-
nosis of “secondary cytosis”. Thus, a total of 75 896 per-
sons were included in the final analyses, including 45 030 
(59.7%) women and 30 866 (40.7%) men. Median age was 
49.0 years (range 19‐99 years) for women and 52.8 years 
(range 18‐99) for men. During the follow‐up period, 2443 
participants died and 580 were lost to follow‐up; 576 emi-
grated and 4 had their civil registration numbers changed. 
Among all women and men, 13.3% and 14.6% were daily 
smokers, stratification on daily amount of tobacco con-
sumption can be seen in Table 1, and 34.4% and 40.5% 
were occasional/ex‐smokers, respectively. The total fol-
low‐up time was 518 977 person‐years, and the mean time 
of follow up was 6.8 years (SD = 0.9 years).
In total, 70 new cases of MPNs were diagnosed among 
the survey participants during the period of follow‐up; 41 
were women and 29 were men. The distribution of MPNs 
was 23 ET, 17 PV, 10 MF, and 27 MPN‐U. Incidence rates 
are available in Table 2. Median age at MPN diagnosis was 
63.0 years (range 21‐86 years). Similar results, shown in 
Table 1, were observed in both the age and sex adjusted 
analysis and the multivariable analysis. The multivariable 
HR of any MPN during the study period for daily smokers 
T A B L E  1  Baseline characteristics of the population from the 
Danish Health Examination Survey study (2007‐2008)
Characteristics Women Men
Participants, n 45 030 30 866
Age, years, median 
(range)
49.0 (19‐99) 52.8 (18‐99)
Smoking status, n (%)
Never 23 561 (52.3) 13 850 (44.9)
Occasional/Ex 15 492 (34.4) 12 509 (40.5)
Daily 5977 (13.3) 4507 (14.6)
≤15 g/day 4187 (9.3) 2580 (8.4)
>15 g/day 1790 (4.0) 1927 (6.2)
Pack‐years, median (10th, 90th percentile)
Occasional/Ex 7.8 (0, 30) 14.0 (0, 44)
Daily 16.0 (3.8, 39) 21.6 (4.8, 50.7)
Marital status, married, 
n (%)
26 430 (58.7) 19 969 (64.7)
Educational level, n (%)
<10 yr 6706 (14.9) 4790 (15.5)
10‐12 yr 8404 (18.7) 7023 (22.8)
≥12 yr 29 920 (66.4) 19 053 (61.7)
Self‐rated healtha, low, 
n (%)
11 087 (24.6) 7487 (24.3)
Body mass index, n (%)b
<25 kg/m2 27 469 (61.0) 13 656 (44.2)
25‐30 kg/m2 11 135 (24.7) 12 629 (40.9)
>30 kg/m2 4614 (10.3) 3259 (10.6)
aSelf‐rated health was assessed by the question “in general, would you say that 
your health is excellent, very good, good, fair, or poor?,” and low self‐rated health 
was defined by combining the latter three categories. 
bNumbers do not sum up to 100% due to missing information. 
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was 2.5 (95% CI: 1.3‐5.0) and 1.9 (95% CI: 1.1‐3.3) for oc-
casional/ex‐smokers. Stratified by MPN subtype, only the 
risk estimate of MPN‐U was significantly increased with 
a HR of 6.2 (95% CI: 1.5‐25) among daily smokers and 
6.2 (95% CI: 1.8‐21) among occasional/ex‐smokers. The 
HRs of all MPN subtypes are presented in Table 2. For 
daily amount of smoking, analysis showed that participants 
who smoked >15 g/day had a HR of 3.4 (95% CI: 1.4‐8.2), 
while participants who smoked ≤15 g/day had a HR of 2.1 
(95% CI: 0.9‐4.7) for any MPN compared to never‐smok-
ers. For cumulative smoking, analysis showed a HR of 1.14 
(95% CI: 1.06‐1.22, P‐value for trend = 0.0005) per 10 
pack‐years of smoking in ever‐smokers. The HR remained 
significant after adjusting for smoking status, HR = 1.10 
(95% CI: 1.00‐1.21, P‐value for trend = 0.05).
4 |  DISCUSSION
In this study with register‐based follow‐up of the DANHES 
survey participants, we found smoking to be a significant 
risk factor for the development of MPNs. The risk of MPNs 
was 2.5‐fold higher among daily smokers and 1.9‐fold higher 
among occasional/ex‐smokers compared to never‐smok-
ers during follow‐up in the multivariable analyses. For the 
subtype analysis, daily and occasional/ex‐smokers had 
6.2‐fold higher risks of MPN‐U compared to never‐smok-
ers. Concerning ET, PV, and MF, the HRs for daily smok-
ers were all above one, although not statistically significant. 
However, caution should be taken when interpreting these 
results as they are likely affected by the low number of cases 
because of a relatively short follow‐up period combined with 
the fact that MPNs are rare diseases,24 with approximately 
500 patients being diagnosed each year in Denmark, with a 
population of approximately 5.5 million people.25 The ob-
served dose–response relationship with a HR of 1.10 for any 
MPN per 10 pack‐years of smoking, as well as the observed 
3.4‐fold and 2.1‐fold (95% CI: 0.9‐4.7) increased risk of any 
MPN in participants who smoked >15 g/day and ≤15 g/day, 
respectively, support the proposed concept of smoking as a 
potent inflammatory stimulus driving the MPN development; 
however, the observed associations are not conclusive per se.
In line with the findings in this study, Kroll et al6 reported 
an increased risk of myeloproliferative diseases, including 
both classical MPNs, myelodysplastic syndrome, chronic my-
elogenous leukemia, and other myeloproliferative disorders, 
among smokers (relative risk of 1.42 (95% CI: 1.31‐1.55) 
per 10 cigarettes/day). However, this study did not inves-
tigate classical MPNs alone. Leal et al7 found that current 
smokers had an increased risk of all MPNs as well (relative 
risk of 1.72 [95% CI: 1.16‐2.56]). This showed mainly to be 
due to the risk of PV, as the risk of ET was nonsignificant. 
MF and MPN‐U were not investigated separately. In contrast 
to the present study, both studies were performed on mid-
dle‐aged women. Most recently, a Danish single‐institution 
case–control study found an association between history of 
smoking in a general MPN population compared to patients 
with chronic lymphocytic leukemia.8 It should be mentioned 
T A B L E  2  Hazard ratios of myeloproliferative neoplasms by smoking status with never‐smokers as the reference group. Age and sex‐adjusted 
and multivariable analysis
MPN, total ET PV MF MPN‐U
Person‐years at risk, yr 518 977 519 110 519 144 519 084 519 118
Events, n
Never‐smokers 20 9 7 3 3
Occasional/ex‐smokers 35 10 6 3 18
Daily smokers 15 4 4 4 6
Total 70 23 17 10 27
Incidence rate per 100 000 
person‐years
13.5 4.4 3.3 1.9 5.2
Smoking status, HR (95% CI)
Age and sex‐adjusted
Occasional/Ex 1.9 (1.1‐3.3) 1.5 (0.6‐3.8) 0.8 (0.3‐2.4) 0.9 (0.2‐4.4) 6.0 (1.8‐21)
Daily 2.6 (1.3‐5.1) 1.7 (0.5‐5.6) 1.7 (0.5‐6.0) 4.4 (1.0‐20.0) 6.9 (1.7‐28)
Multi‐adjusted ῲ
Occasional/Ex 1.9 (1.1‐3.3) 1.5 (0.6‐3.7) 0.8 (0.3‐2.4) 0.9 (0.2‐4.4) 6.2 (1.8‐21)
Daily 2.5 (1.3‐5.0) 1.8 (0.5‐5.8) 1.7 (0.5‐5.8) 4.3 (0.9‐19) 6.2 (1.5‐25)
ET, essential thrombocytosis; MF, myelofibrosis; MPN, myeloproliferative neoplasms; MPN‐U, unclassifiable myeloproliferative neoplasm; PV, polycythemia vera; ῲ, 
Adjusted for age, sex, body mass index, and education level.
5800 |   PEDERSEN Et al.
as well, that conflicting with the above‐mentioned results 
and the results in the present study, two earlier case–control 
studies could not find an association between smoking and 
risk of MPNs.26,27 Pasqualetti et al26 pooled together CML 
(n = 69), idiopathic myelofibrosis (n = 11), PV (n = 8), and 
idiopathic thrombocythemia (n = 4), thereby increasing the 
heterogenicity and subsequently lowering the comparability 
with the present study. Mele et al27 only investigated cases 
of ET (n = 39) and smoking exposure was barely defined, 
thereby obscuring the transparency and conclusion of the 
study. Most recently, existing studies have been compiled in 
a meta‐analysis with 1 368 738 individuals and 2017 MPN 
cases.28 Pooled odds ratio for MPNs were 1.44 (95% CI: 
1.33‐1.56) comparing smokers to nonsmokers; 1.10 (95% CI: 
0.86‐1.41) comparing ex‐smokers to nonsmokers; and 1.30 
(95% CI: 1.14‐1.49) comparing ever‐smokers to never smok-
ers. In subgroup analysis, smokers had a statistically signifi-
cantly increased risk of ET; however, odds ratios were above 
one for both PV and MF.
The association found is supported by the many molecular 
and cellular similarities between the consequences of smok-
ing and MPNs and has most recently been described as “The 
Smoke‐MPN‐Cancer Loop.”3 One of many inflammatory 
cytokines increased in smokers and playing a role in MPN 
pathogenesis is tumor necrosis factor alpha, which, in addition 
to nuclear factor kappa beta (NF‐kβ) upregulation, has been 
shown to facilitate clonal expansion in JAK2‐V617F‐bearing 
cells.7,29 NF‐kβ is also associated with increased production 
of transforming growth factor beta and vascular endothelial 
growth factor,11 both highly immunosuppressive cytokines that 
are elevated in the circulation in MPNs and markedly expressed 
in the bone marrow.5,30 Both cytokines may induce qualitative 
and quantitative alterations in immune cells, thereby poten-
tially impairing the functionality of these immune cells and 
consequently “tumor immune surveillance,” the ultimate out-
come being expansion of the malignant clone.4,5,30 Smoking 
is also associated with increased hypoxia‐inducible factor sig-
naling12 and interleukin 1‐beta secretion from mononuclear 
cells,31 leading to upregulation of nuclear factor erythoid‐2 ex-
pression in megakaryocytic cells and IL‐8 secretion.10,32 These 
observations are indeed intriguing, as both are believed to play 
a vigorous role in MPN‐pathogenesis as well.33,34
This cohort study, with focus on risk of MPNs in smok-
ers, is, to our knowledge, the first in a general population 
including both women and men. Additionally, by including 
75 896 individuals, it is the largest cohort study focusing 
isolated on smoking as a risk factor for classical MPNs as 
the comprehensive study by Kroll et al6 pooled myelop-
roliferative and myelodysplastic disorders among other di-
agnoses in their analyses. The main strengths in the study 
are the size of the cohort and the use of valid population‐
based central administrative registries with minimal loss to 
follow‐up. We were able to include all MPNs among the 
DANHES participants as all MPN patients are followed 
at hospitals in Denmark and hospital diagnoses at Danish 
hospitals must be reported to the Danish National Patient 
Registry.17 In this context, diagnosis codes for hematologi-
cal malignancies are found to be valid.35 Nevertheless, the 
study also has some limitations. Because MPNs can be dif-
ficult to diagnose and the MPN diagnoses in this study was 
not verified by information from medical files, we cannot 
exclude that a few participants could have been misclas-
sified, for example, some heavy smokers could have been 
misclassified as having a MPN based upon a secondary cy-
tosis or a reactive thrombocytosis. Although the impact of 
misclassified cases is hard to estimate without access to 
medical files, we are confident that it is minimal, because, 
in Denmark, a bone marrow biopsy is done routinely in all 
individuals suspected of having MPN. However, since pa-
tients who were diagnosed with MPNs and subsequently a 
“secondary cytosis” were excluded, we hereby tried to pre-
vent this bias. Furthermore, we excluded 510 participants 
with missing information on smoking (<1%); in these par-
ticipants, no MPN cases after follow‐up occurred. While 
selective missing bias cannot be ruled out, it does not seem 
that excluded participants had a higher risk as compared 
to participants with non‐missing information on smoking.
Former studies have also investigated risk factors for 
MPNs, and rather convincing associations have been found 
concerning familial MPNs and some autoimmune disor-
ders.36 Also, associations with some occupations and ex-
posures to different toxins are found, although conflicting 
evidence exists in this area.36 As we did not have access to 
this information and due to the possibility, that subtypes of 
MPNs may have various carcinogenesis and, thus, different 
risk factors, we cannot rule out that the results in the present 
study are affected by some degree of residual confounding. 
Furthermore, with surveys, selection and reporting bias is 
possible. DANHES reported that individuals who were un-
married, had the lowest level of education, or lowest cat-
egory of income were under‐represented compared to the 
Danish population.15 Under‐reporting of smoking could 
have occurred in our cohort as 13.3% and 14.6% of women 
and men reported daily smoking. This contrasts with a sur-
vey made upon the request of the Danish Health Authority 
in 2008 on 4523 persons, in which they found 22.3% and 
24.1% of the Danish women and men as daily smokers.37 It 
should also be mentioned that occasional and ex‐smokers 
were combined in the present study. The risk estimate for 
this combined group may be higher than the risk estimate 
would be for a group of pure ex‐smokers because of the 
contribution from occasional smokers. Lastly, as smok-
ing exposure was only reported at the time of inclusion in 
DANHES, we were not able to account for smoking status 
at the time the MPN diagnosis was reported to the Danish 
National Patient Registry.
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In conclusion, we have shown an increased risk of MPNs 
in smokers compared to never‐smokers in a cohort of se-
lected individuals from the general population in Denmark. 
The results of this study support the growing evidence sug-
gesting smoking to be a risk factor in the development of 
MPNs.
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